Kosaku Nitta, Brian Bieber, Angelo Karaboyas, David W Johnson, Talerngsak Kanjanabuch, Yong-Lim Kim, Mark Lambie, John Hartman, Jenny I Shen, Mihran Naljayan, Roberto Pecoits-Filho, Bruce M Robinson, Ronald L Pisoni, Jeffrey Perl, Hideki Kawanishi
BACKGROUND: Mineral bone disorder (MBD) in chronic kidney disease (CKD) is associated with high symptom burden, fractures, vascular calcification, cardiovascular disease and increased morbidity and mortality. CKD-MBD studies have been limited in peritoneal dialysis (PD) patients. Here, we describe calcium and parathyroid hormone (PTH) control, related treatments and mortality associations in PD patients. METHODS: We used data from eight countries (Australia and New Zealand (A/NZ), Canada, Japan, Thailand, South Korea, United Kingdom, United States (US)) participating in the prospective cohort Peritoneal Dialysis Outcomes and Practice Patterns Study (2014-2022) among patients receiving PD for >3 months...
March 19, 2024: Peritoneal Dialysis International